DeepMed Research

BAKER HEART AND DIABETES INSTITUTE

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Established: 1858-01-01

Employees: 481

Market Cap: -

Website: http://www.bakeru.edu

Clinical Trials

Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)

Phase 4

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: Agomelatine
Drug: Escitalopram

First Posted Date: 2011-12-01

Last Posted Date: 2013-12-18

Lead Sponsor: Baker Heart and Diabetes Institute

Target Recruit Count: 40

Registration Number: NCT01483053

Locations: 🇦🇺
Monash Medical Centre - Monash Health, Clayton, Victoria, Australia
🇦🇺
Alfred and Baker Medical Unit - Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺
Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia

The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

Phase 4

Conditions: Abdominal Obesity
Hypertension

Interventions: Drug: Moxonidine
Drug: Irbesartan

First Posted Date: 2011-05-26

Last Posted Date: 2012-02-03

Lead Sponsor: Baker Heart and Diabetes Institute

Target Recruit Count: 100

Registration Number: NCT01360710

Locations: 🇦🇺
BakerIDI Heart and Diabetes Institute, Prahran, Victoria, Australia

Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity

Phase 4

Conditions: Obesity
Overweight

Interventions: Drug: Moxonidine (Physiotens)
Other: Dietary intervention

First Posted Date: 2010-08-12

Last Posted Date: 2013-11-05

Lead Sponsor: Baker Heart and Diabetes Institute

Target Recruit Count: 77

Registration Number: NCT01180231

Locations: 🇦🇺
BakerIDI Heart and Diabetes Institute, Prahran, Victoria, Australia

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Phase 4

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: Placebo
Drug: Moxonidine

First Posted Date: 2010-03-29

Last Posted Date: 2023-09-14

Lead Sponsor: Baker Heart and Diabetes Institute

Target Recruit Count: 48

Registration Number: NCT01094769

Locations: 🇦🇺
Alfred & Baker Medical Unit, Melbourne, Victoria, Australia

Effect of Ghrelin on Sympathetic Nervous System

Not Applicable

Completed

Conditions: Healthy
Obesity

First Posted Date: 2009-06-03

Last Posted Date: 2023-09-14

Lead Sponsor: Baker Heart and Diabetes Institute

Target Recruit Count: 46

Registration Number: NCT00912587

Locations: 🇦🇺
Alfred & Baker Medical Unit, Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy